-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At the end of 2021, following news of layoffs by Novo Nordisk, Sanofi and other multinational pharmaceutical companies involved in the centralized procurement of insulin, as well as news of layoffs by AstraZeneca and Ogalon, a number of multinational pharmaceutical companies have recently joined the layoffs Team, of which Bojian will lay off more than 1,000 people
.
Bojian may lay off thousands of employees due to poor product performance.
According to Bojian’s third-quarter financial report, the sales of Alzheimer’s disease (AD) drug Aduhelm after the listing was only 300,000 US dollars.
Subsequently, Aduhelm brain edema side effects, European listing Issues such as applications or rejections continue to ferment
.
Aduhelm was approved by the FDA in June 2021 for the treatment of early Alzheimer's disease (AD)
.
Recently, it was reported that Bojian plans to lay off more than 1,000 employees due to poor product performance and use it to save up to 750 million U.
S.
dollars to deal with disputes about Aduhelm
.
There are reports that the plan may come before the Christmas holiday this year
.
At the same time, Alfred Sandrock, Bojian's chief research and development officer, will leave with him
.
It is reported that Sandrock announced that it will leave the company at the end of 2021
.
It left or was forced to take responsibility for Aduhelm’s controversial approval and its poor listing performance
.
Boston Scientific announced layoffs, about 170 people.
Recently, cardiovascular giant Boston Scientific announced the closure of its manufacturing plant in Silicon Valley.
The plan will be accompanied by layoffs of 170 people
.
It is reported that the company has submitted a notice to California in early December to close its manufacturing plant in Silicon Valley and lay off employees.
This action will take effect on January 30, 2022
.
Regarding the layoffs, the company said that the business transfer of the San Jose (Silicon Valley) plant in California is part of the company's restructuring plan announced in 2018
.
After the transfer, it will help the company adjust its products, technology and resources
.
Utimes Bi Pharmaceuticals plans to lay off its employees due to two failures of its products due to medical insurance
.
The product line adjusted this time is Yopro (rotigotine).
The reason for the layoffs is that Yopro (rotigotine) has negotiated national medical insurance twice, but they are not eligible for medical insurance.
In this regard, the company believes that the product The overall output was too low and the business volume was not enough
.
This adjustment plan was implemented .
However, because this product line is only one product, there are not many domestic sales representatives, so the company plans to carry out internal transfer or a small number of layoffs.
The specific compensation plan has not been announced
.
According to data, in June 2018, Utimes announced that its innovative drug Yopro (rotigotine patch) was approved by the National Food and Drug Administration for single-agent therapy (not combined with levodopa) for early idiosyncratic development Symptoms and signs of Parkinson's disease, or combined with levodopa for the treatment of various stages in the course of the disease
.
On November 4 of the same year, UCP announced that its innovative drug Yopro (rotigotine patch) was officially launched in China, and on October 17, it issued its first prescription to bring about 2.
6 million Parkinson’s disease patients in China.
Come to a new choice
.
Post-Edition In recent years, under the changes in the pharmaceutical market, many pharmaceutical companies have faced greater pressure on their performance, and transformation is also imminent.
In this context, news of layoffs accompanied by business adjustments has continued
.
It is reported that the wave of layoffs in multinational pharmaceutical companies has continued to emerge this year, including Sanofi, Amgen, Gilead, Novartis, GlaxoSmithKline, Mylan, Gilead, Johnson & Johnson, AstraZeneca, and many other layoffs throughout the year.
.
There is less than half a month left at the end of 2021, but the personnel adjustment of multinational pharmaceutical companies is still accelerating, and the industry expects that the layoffs in 2022 will also accelerate
.
.
Bojian may lay off thousands of employees due to poor product performance.
According to Bojian’s third-quarter financial report, the sales of Alzheimer’s disease (AD) drug Aduhelm after the listing was only 300,000 US dollars.
Subsequently, Aduhelm brain edema side effects, European listing Issues such as applications or rejections continue to ferment
.
Aduhelm was approved by the FDA in June 2021 for the treatment of early Alzheimer's disease (AD)
.
Recently, it was reported that Bojian plans to lay off more than 1,000 employees due to poor product performance and use it to save up to 750 million U.
S.
dollars to deal with disputes about Aduhelm
.
There are reports that the plan may come before the Christmas holiday this year
.
At the same time, Alfred Sandrock, Bojian's chief research and development officer, will leave with him
.
It is reported that Sandrock announced that it will leave the company at the end of 2021
.
It left or was forced to take responsibility for Aduhelm’s controversial approval and its poor listing performance
.
Boston Scientific announced layoffs, about 170 people.
Recently, cardiovascular giant Boston Scientific announced the closure of its manufacturing plant in Silicon Valley.
The plan will be accompanied by layoffs of 170 people
.
It is reported that the company has submitted a notice to California in early December to close its manufacturing plant in Silicon Valley and lay off employees.
This action will take effect on January 30, 2022
.
Regarding the layoffs, the company said that the business transfer of the San Jose (Silicon Valley) plant in California is part of the company's restructuring plan announced in 2018
.
After the transfer, it will help the company adjust its products, technology and resources
.
Utimes Bi Pharmaceuticals plans to lay off its employees due to two failures of its products due to medical insurance
.
The product line adjusted this time is Yopro (rotigotine).
The reason for the layoffs is that Yopro (rotigotine) has negotiated national medical insurance twice, but they are not eligible for medical insurance.
In this regard, the company believes that the product The overall output was too low and the business volume was not enough
.
This adjustment plan was implemented .
However, because this product line is only one product, there are not many domestic sales representatives, so the company plans to carry out internal transfer or a small number of layoffs.
The specific compensation plan has not been announced
.
According to data, in June 2018, Utimes announced that its innovative drug Yopro (rotigotine patch) was approved by the National Food and Drug Administration for single-agent therapy (not combined with levodopa) for early idiosyncratic development Symptoms and signs of Parkinson's disease, or combined with levodopa for the treatment of various stages in the course of the disease
.
On November 4 of the same year, UCP announced that its innovative drug Yopro (rotigotine patch) was officially launched in China, and on October 17, it issued its first prescription to bring about 2.
6 million Parkinson’s disease patients in China.
Come to a new choice
.
Post-Edition In recent years, under the changes in the pharmaceutical market, many pharmaceutical companies have faced greater pressure on their performance, and transformation is also imminent.
In this context, news of layoffs accompanied by business adjustments has continued
.
It is reported that the wave of layoffs in multinational pharmaceutical companies has continued to emerge this year, including Sanofi, Amgen, Gilead, Novartis, GlaxoSmithKline, Mylan, Gilead, Johnson & Johnson, AstraZeneca, and many other layoffs throughout the year.
.
There is less than half a month left at the end of 2021, but the personnel adjustment of multinational pharmaceutical companies is still accelerating, and the industry expects that the layoffs in 2022 will also accelerate
.
